Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972148 | 1.00 | CA2 (0.50) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL31424266 | 1.00 | CA2 (0.50) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL12883057 | 0.98 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL22710100 | 0.98 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL13248148 | 0.98 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9972151 | 0.98 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9798873 | 0.92 | CA2 (0.46) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9798886 | 0.92 | CA2 (0.46) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL10452650 | 0.92 | CA2 (0.46) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL7875753 | 0.85 | CA2 (0.59) | CA2TSHRSMN1; SMN2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-5068340-A | Antagonist of platelet activating factor for treatment of asthma, inflammation or shock | SANKYO COMPANY, LIMITED (JP) | 1991-11-26 | — | — | US | disclosed |
| EP-0238202-A2 | Glycerol derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | PHOSPHO1, PTDSS1, PTDSS2 | CA2 3169/4885TSHR 4168/4885SMN1; SMN2 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.